Hanmi Science Co (008930.KS) Osake Kurssi
Hanmi Science Co Kurssi
Liikevaihto on kasvanut 6,0 % vuodessa viimeisten 19 vuoden aikana 1,36 T KRW:een. Osakekohtainen tulos on kasvanut 2,6 % vuodessa viimeisten 19 vuoden aikana. Hanmi Science Con nettomarginaali on nyt 8,7 %, noussut 4,5 %:sta muutama vuosi sitten. Hanmi Science Con osinkotuotto on tällä hetkellä noin 0,57 %. Jakosuhde on noin 32 % tuloksesta.
Hanmi Science Co osakekurssi
Hanmi Science Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Hanmi Science Co -osakkeesta
The business model of Hanmi Science Co Ltd., a South Korean company, revolves around its expertise in the field of biotechnology. Hanmi Science focuses on the development, manufacturing, and distribution of innovative pharmaceutical products. The company is committed to researching and creating cutting-edge drugs and therapies to address various medical conditions and improve patient outcomes. With a strong emphasis on research and development, Hanmi Science aims to enhance global healthcare by delivering novel treatment options to customers worldwide.
Hanmi Science Co Ltd is primarily active in the pharmaceutical and healthcare industries.
Hanmi Science Co Ltd faces competition from various companies in the market. Some of its main competitors include CJ Healthcare Corp, SK Biopharmaceuticals Co Ltd, and Yuhan Corporation. These competitors are also prominent players in the pharmaceutical and biotechnology industry.
Hanmi Science Co Ltd is a leading company in the healthcare industry. Established in 1973, Hanmi Science Co Ltd has a rich history of over four decades. The company focuses on research, development, and manufacturing of innovative medical devices and pharmaceutical products. With a strong commitment to improving global healthcare, Hanmi Science Co Ltd has made significant contributions to the industry. They have formed strategic partnerships and collaborations with renowned companies to enhance their capabilities and expand their global presence. Hanmi Science Co Ltd's dedication to quality, innovation, and customer satisfaction has positioned them as a trusted and reliable name in the healthcare sector.
Hanmi Science Co Ltd has achieved several significant milestones in its corporate history. The company made its debut in 1973 as a small chemical trading business and has since evolved into a leading global provider of pharmaceutical and healthcare solutions. Hanmi Science Co Ltd successfully developed and launched its first original drug, LUSEDRA, in 2008, marking a major advancement in the pharmaceutical sector. Additionally, the company has established numerous strategic partnerships and collaborations with global pharmaceutical giants, enabling it to enhance its research and development capabilities. Hanmi Science Co Ltd continues to foster innovation, expand its product pipeline, and deliver breakthrough treatments to improve patient outcomes.
Hanmi Science Co Ltd is primarily present in South Korea.
Hanmi Science Co Ltd represents values of innovation, excellence, and customer satisfaction. With a strong corporate philosophy focused on pioneering new technologies and providing top-notch services, Hanmi Science Co Ltd aims to meet the ever-evolving needs of its clients. By prioritizing research and development, the company strives to deliver cutting-edge solutions in the fields of biotechnology and pharmaceuticals. With a commitment to ethical practices, Hanmi Science Co Ltd also emphasizes integrity and social responsibility in its operations. Through its dedication to these values and its forward-thinking approach, Hanmi Science Co Ltd continues to make significant contributions to the industry.
Nykyisellä valuuttakurssilla Hanmi Science Co-osake noteerataan hintaan 35,24 EUR (53 000,00 KRW).
Hanmi Science Co-osake (008930.KS) on listattuna 1 pörssissä, muun muassa: KOSPI (Seoul) (008930.KS).
Hanmi Science Co Ltd is a leading company in the pharmaceutical industry that specializes in the research and development of innovative drugs and medical devices. The company offers a wide range of products and services divided into various business areas.
Liikevaihtoa ei voida laskea Hanmi Science Co:lle tällä hetkellä.
Voittoa ei voida laskea Hanmi Science Co:lle tällä hetkellä.
P/E-suhdetta ei voida laskea Hanmi Science Co:lle tällä hetkellä.
P/S-suhdetta ei voida laskea Hanmi Science Co:lle tällä hetkellä.
Hanmi Science Co:n Eulpool-laatuscore on 5/10.
Hanmi Science Co:n ISIN on KR7008930000. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Hanmi Science Co:n ticker on 008930.KS. Tämä pörssinoteeraus käytetään Hanmi Science Co-osakkeiden kauppaan pörssissä.
Hanmi Science Co osake
Hanmi Science Co vertaisryhmä
Hanmi Science Co Ticker
Hanmi Science Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Hanmi Science Co:sta
Meidän osakeanalyysimme Hanmi Science Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Hanmi Science Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: